Privi Speciality Chemicals Limited (PRIVISCL) AI Stock Analysis

• Market Cap: ₹105.30B
• Dividend Yield: 0.15%
• Average Volume (3M): 4.45K
• Price to Earnings (P/E): 39.5
• Beta (1Y): 0.80
• Revenue Growth: 24.25%
• EPS Growth: 96.45%
• Country: IN
• Employees: 711
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 24.00
• Shares Outstanding: 39,062,702
• 10 Day Avg. Volume: 6,483
• 30 Day Avg. Volume: 4,450
• PEG Ratio: 0.38
• Price to Book (P/B): 6.33
• Price to Sales (P/S): 3.32
• P/FCF Ratio: -387.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ₹3,261.00 ▲(17.37% Upside)

Privi Speciality Chemicals Limited's overall score is driven by strong financial performance, particularly in revenue growth and profitability. However, the high P/E ratio and negative free cash flow due to capital expenditures are concerns. Technical indicators show mixed signals, with potential upward momentum but also oversold conditions.

Positive Factors

Revenue Growth

Strong revenue growth indicates increasing demand and successful market expansion, supporting long-term business sustainability and profitability.

Profitability

High profit margins reflect effective cost management and pricing power, contributing to the company's financial health and competitive advantage.

Cash Generation

Strong cash generation supports operational needs and strategic investments, enhancing financial flexibility and resilience against market fluctuations.

Negative Factors

Free Cash Flow

Negative free cash flow due to high capital expenditures could strain liquidity, limiting the company's ability to invest in growth opportunities.

Capital Expenditures

High capital expenditures, while potentially beneficial long-term, can pressure short-term cash flow, impacting immediate financial flexibility.

Debt Levels

While currently manageable, increased debt levels could pose risks if not matched by proportional growth in earnings and cash flow.

Privi Speciality Chemicals Limited Business Overview & Revenue Model

Company Description

Privi Speciality Chemicals Limited operates as a manufacturer, supplier, and exporter of aroma and fragrance chemicals in India and internationally. It offers amber fleur, acetates, dihydromyrcenol, ionones, nitriles, sandal wood derivatives, and specialty chemicals, as well as bulk aroma chemicals; and nutraceutical products. The company also provides aroma chemicals, such as alpha damascone, alpha ionone, alpha terpenyl acetate, amber fleur, amber gamma, beta iso damascol, BI perfumery grade, BI technical grade, carene-60 & Carene-90, cedar ketol, citronellal, citronellyl acetate, citronellyl nitrile, dipentene, double distilled turpentine oil, dihydro myrcenol, dihydromyrcene, gamma methyl ionone, gamma terpenyl acetate, geraniol, geranyl acetate, Indian sandal core, ionone, iso boronyl acetate, l-limonene, methyl ionone, nerol, neryl acetate, nimberol, OTBCHA, pine oil, prionyl, PTBCHA, terpeniol alpha, terpeniol gamma, terpeniol MU &BP grade, terpinolene, sandal fleur, sandal touch, tetrahydroflorol, tetrahydrogeraniol, tetrahydrogeranyl acetate, tetrahydromyrcenol, timber forte, and timber touch. The company was formerly known as Fairchem Speciality Limited and changed its name to Privi Speciality Chemicals Limited in October 2020. Privi Speciality Chemicals Limited was incorporated in 1985 and is based in Mumbai, India.

How the Company Makes Money

Privi Speciality Chemicals Limited generates revenue through multiple key streams, primarily from the sale of specialty chemicals tailored for specific industries. The company operates on a B2B model, supplying its products to manufacturers in agrochemicals, personal care, and pharmaceuticals, which often require bespoke chemical solutions. Additionally, PRIVISCL has established strategic partnerships with major corporations to enhance its market reach and product offerings, thus creating additional revenue opportunities. The company's focus on R&D enables it to innovate and introduce new products, driving sales growth. Furthermore, the increasing global demand for sustainable and eco-friendly chemicals positions PRIVISCL to capitalize on emerging market trends, contributing significantly to its earnings.

Privi Speciality Chemicals Limited Financial Statement Overview

Summary

Privi Speciality Chemicals Limited shows strong revenue growth and profitability with a robust gross profit margin and improved net profit margin. The balance sheet is solid with reasonable leverage, but negative free cash flow due to high capital expenditures poses a liquidity risk.

Income Statement

Privi Speciality Chemicals Limited has demonstrated a robust revenue growth rate of 19.9% from 2024 to 2025, indicating strong demand and expansion. The gross profit margin stands at a healthy 38.9%, and the net profit margin improved to 8.9% in 2025, reflecting enhanced profitability. However, the EBIT margin is notably high at 34.7%, suggesting significant operational efficiency. EBITDA margin has decreased from the previous year but remains substantial at 21.4%. Overall, the company shows positive growth and profitability trends.

Balance Sheet

The debt-to-equity ratio is 1.04, showing a balanced leverage position, while the return on equity (ROE) improved to 16.9% in 2025, indicating effective utilization of equity capital. The equity ratio is stable at 39.5%, reflecting a sound capital structure. Despite a slight increase in debt levels, the company maintains a managed balance sheet with adequate equity backing its assets.

Cash Flow

Operating cash flow to net income ratio is 1.50, indicating strong cash generation relative to net earnings. However, the free cash flow has turned negative in 2025, primarily due to capital expenditures exceeding operating cash flows. The free cash flow to net income ratio is negative, highlighting potential liquidity constraints. Although operating cash flows are robust, the significant outflow for capital investments is a concern for free cash flow sustainability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	21.96B	21.01B	17.52B	16.08B	14.04B	12.77B
Gross Profit	8.77B	8.01B	5.91B	4.80B	4.57B	5.11B
EBITDA	4.78B	4.46B	3.18B	1.79B	1.90B	2.04B
Net Income	2.18B	1.87B	949.07M	222.15M	973.80M	1.17B
Balance Sheet
Total Assets	0.00	27.91B	23.43B	23.91B	21.76B	15.40B
Cash, Cash Equivalents and Short-Term Investments	573.04M	577.31M	635.46M	271.77M	445.19M	154.53M
Total Debt	0.00	11.43B	10.08B	10.79B	9.30B	5.37B
Total Liabilities	-11.18B	16.73B	14.01B	15.56B	13.56B	8.18B
Stockholders Equity	11.18B	11.03B	9.24B	8.29B	8.12B	7.23B
Cash Flow
Free Cash Flow	0.00	-180.27M	2.04B	-909.33M	-3.04B	-706.96M
Operating Cash Flow	0.00	2.81B	3.54B	487.59M	47.36M	1.72B
Investing Cash Flow	0.00	-2.94B	-1.80B	-1.33B	-3.20B	-2.42B
Financing Cash Flow	0.00	386.33M	-1.71B	723.05M	3.33B	229.48M

Privi Speciality Chemicals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2778.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PRIVISCL, the sentiment is Negative. The current price of 2778.5 is below the 20-day moving average (MA) of 3009.33, below the 50-day MA of 3096.27, and above the 200-day MA of 2490.13, indicating a neutral trend. The MACD of -103.47 indicates Positive momentum. The RSI at 36.68 is Neutral, neither overbought nor oversold. The STOCH value of 15.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PRIVISCL.

Privi Speciality Chemicals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FCL	75 Outperform	₹26.65B	27.17	―	0.65%	-10.12%	-22.38%
PRIVISCL	64 Neutral	₹105.30B	39.47	―	0.15%	24.25%	96.45%
NCC	64 Neutral	₹93.36B	11.76	―	1.37%	-5.66%	-4.66%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ALKYLAMINE	61 Neutral	₹79.67B	43.73	―	0.62%	3.95%	8.28%
ACI	58 Neutral	₹63.67B	37.27	―	0.78%	-3.15%	-22.30%
SUDARSCHEM	49 Neutral	₹74.19B	133.90	―	0.46%	159.81%	-63.02%

Privi Speciality Chemicals Limited Corporate Events

Privi Speciality Chemicals Board Clears Merger of Group Entities Into Listed Parent

Privi Speciality Chemicals Limited’s board has approved a Scheme of Amalgamation to merge Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited, its wholly owned subsidiary, into the listed parent company, subject to approvals from shareholders, creditors, the National Company Law Tribunal and other regulators under the Companies Act, 2013. The transaction, classified as a related-party deal, will be executed on the basis of an independent valuation and fairness opinion, aiming to dissolve the transferor entities without winding up, streamline the group structure, and potentially enhance operational efficiency and balance sheet clarity for investors and other stakeholders.

Privi Speciality Chemicals Board Clears Merger of Key Subsidiaries

Privi Speciality Chemicals Limited’s board has approved a Scheme of Amalgamation to merge Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited, its wholly owned subsidiary, into the listed parent company. The proposed restructuring, carried out under the Companies Act and subject to approvals from shareholders, creditors, the National Company Law Tribunal and regulators, will dissolve the transferor entities without winding up while issuing Privi Speciality shares to shareholders of Privi Fine Sciences based on an independent valuation and fairness opinion, consolidating assets, turnover and net worth within the listed entity and simplifying the group structure as a related-party transaction executed at arm’s length.